Download | - View final version: Pharmacokinetics and pharmacodynamic effect of a blood-brain barrier-crossing fusion protein therapeutic for Alzheimer’s disease in rat and dog (PDF, 1.2 MiB)
|
---|
DOI | Resolve DOI: https://doi.org/10.1007/s11095-022-03285-z |
---|
Author | Search for: Lessard, Etienne1; Search for: Rennie, Kerry1; Search for: Haqqani, Arsalan1; Search for: Ling, Binbing1; Search for: Whitfield, James1; Search for: Paradis, Andrea; Search for: Araujo, Joseph; Search for: Yoganathan, Nathan; Search for: Gillard, John; Search for: Stanimirovic, Danica1; Search for: Chakravarthy, Balu1 |
---|
Affiliation | - National Research Council of Canada. Human Health Therapeutics
|
---|
Format | Text, Article |
---|
Subject | Alzheimer's disease; blood-brain barrier-crossing biologics; CNS exposure; pharmacodynamics; pharmacokinetics |
---|
Abstract | We have recently demonstrated the brain-delivery of an Amyloid-ß oligomer (Aßo)-binding peptide-therapeutic fused to the BBB-crossing single domain antibody FC5. The bi-functional fusion protein, FC5-mFc-ABP (KG207-M) lowered both CSF and brain Aß levels after systemic dosing in transgenic mouse and rat models of Alzheimer’s disease (AD). For development as a human therapeutic, we have humanized and further engineered the fusion protein named KG207-H. The purpose of the present study was to carry out comparative PK/PD studies of KG207-H in wild type rat and beagle dogs (middle-aged and older) to determine comparability of systemic PK and CSF exposure between rodent species and larger animals with more complex brain structure such as dogs. |
---|
Publication date | 2022-06-15 |
---|
Publisher | Springer Nature |
---|
Licence | |
---|
In | |
---|
Language | English |
---|
Peer reviewed | Yes |
---|
Identifier | 3285 |
---|
Export citation | Export as RIS |
---|
Report a correction | Report a correction (opens in a new tab) |
---|
Record identifier | f46400b2-446c-49ba-a6c4-94eb4f15a6c2 |
---|
Record created | 2024-02-27 |
---|
Record modified | 2024-02-27 |
---|